HomeLatest Startup News & Updates for Indian EntrepreneursViatris' Global Biosimilars Business...

Viatris’ Global Biosimilars Business is now fully acquired by Biocon Biologics

BENGALURU, India | 2nd December 2022: Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS).

Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors.

Effective from the date of closing, Biocon Biologics will recognize the combined revenue and associated profits from the acquired products, a step-up from the existing profit share arrangement.

Strategic Rationale

The acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.

The integration of Viatris’ acquired global biosimilars business and Biocon Biologics’ existing capabilities in research and development, global scale manufacturing and commercialization in several emerging markets positions  Biocon Biologics as a unique, fully integrated, leading global biosimilars player that is well placed to provide equitable access to high quality, lifesaving biosimilar medicines to patients across the globe. With this acquisition Biocon Biologics emerges as a world leading biosimilars player with eight commercialized products.

With the closing of the deal, Biocon Biologics has full ownership of its collaboration assets, bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bPertuzumab and bGlargine 300U, as well as Viatris’ rights for the in-licensed immunology products of bAdalimumab and bEtanercept. Biocon Biologics has also acquired Viatris’ rights for bAflibercept, which is used to treat several ophthalmology conditions. Viatris has been the ‘first to file’ bAflibercept in the U.S.

Biocon Biologics has a unique portfolio of 20 biosimilar assets, including insulins and monoclonal antibodies spanning therapy areas such as diabetes, oncology, immunology and ophthalmology. With one of the broadest and deepest biosimilar portfolios in the industry, Biocon Biologics can make a meaningful difference to patients’ lives and deliver significant savings to healthcare systems around the world.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, said: “The completion of the acquisition of Viatris’ global biosimilars business is a historic inflection point in Biocon Biologics’ journey of becoming a world leading, fully integrated biosimilars enterprise, committed to serve patients’ needs for affordable access to essential biomedicines. It will fast-track our direct entry into several advanced and emerging markets. This acquisition builds on our decade-long partnership and will enable us to realize our vision of addressing global health inequities. I believe this move will strengthen our value proposition to deliver long-term value to Biocon and Biocon Biologics shareholders.”

“To ensure seamless continuity of services to patients and customers, Viatris will continue to work with our teams for a transition period of up to two years. I would like to thank the teams at both Biocon Biologics and Viatris that have worked together to address regulatory and statutory requirements to enable deal closure,” she added.

Robert J. Coury, Viatris’ Executive Chairman, said: “I am extremely pleased to have reached this monumental moment for Biocon Biologics. As a significant shareholder in Biocon Biologics, we are committed to ensuring the long-term success of the company and maximizing the value of what we are building together – a new world-class, fully integrated biosimilars leader.”

The acquisition of Viatris’ global biosimilars business is unique as it cements the long- standing strategic partnership between the two companies, who have been successfully collaborating for more than a decade. As a unique, fully integrated organization driven by a common purpose, Biocon Biologics aspires to expand access and enhance the quality of experience of customers, partners and patients.

Funding of the Transaction

As a part of completing the transaction, Biocon Biologics has issued Compulsorily Convertible Preference Shares (CCPS) in the Company valued at USD 1 billion, equivalent to an equity stake of at least 12.9% on a fully diluted basis, and made an upfront cash payment of USD 2 billion to Viatris.

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded through an equity infusion of USD 650 million by Biocon Limited and USD 150 million by Serum Institute Life Sciences (SILS).  Biocon Limited’s funding comprises USD 230 million from existing reserves and USD 420 million through mezzanine financing. Biocon is in the process of securing investments to retire the mezzanine financing, post deal closure.

Post conclusion of the Viatris and Serum transactions, Biocon Limited’s stake in Biocon Biologics will be 68%.

Sustainability Linked Loan

Under the SLL, Biocon Biologics has committed to achieve progress on important sustainability linked Key Performance Indicators (KPIs) related to (i) Improving biosimilars access, (ii) Enhancing diversity and inclusion in the workforce; (iii) Increasing the use of green power; and (iv) Reduction in fresh water consumption.

This is the largest SLL linked loan among pharmaceutical and biomanufacturing companies in the Asia-Pacific region, reaffirming Biocon Group’s commitment to ensure sustainable performance across the operational, financial, environmental, social and governance facets of its businesses.

Ensuring Smooth Transition

To ensure seamless business continuity and allow for a gradual integration of people and business activities, Viatris will provide commercial and other transition services to Biocon Biologics for up to two years. The two companies have also put in place   Governance Committees and an Integration Management Office to ensure smooth execution and integration during the transition period.

Rajiv Malik, President of Viatris, has joined the Board of Directors of Biocon Biologics Ltd, effective Nov 29, 2022. Kiran Mazumdar-Shaw will continue as the Executive Chairperson of Biocon Biologics Ltd. 

Most Popular

More from Author

Business Leaders Give Thumbs Up to Union Budget 2023’s Growth-Focused Provisions

Understand the impact of the Union Budget 2023-24 on the Indian economy through the eyes of business leaders and why they are optimistic about its potential.

Read Now

Youngsters are Taking Charge of their Financial Future through Real Estate

Gurugram, Haryana, India | 3rd February 2023: Saurabh Thareja, Director of  Urban Plus Infra build says we cannot deny the fact that investing in real estate is a great way to build wealth. Getting started with real estate investing at a young age is a great idea for several...

Real Estate Players Hails Budget 2023: Lauds Government’s Move to Boost Infrastructure

New Delhi, Delhi, India | 3rd February 2023: India's real estate fraternity has reacted positively to the Union Budget 2023 presented by the Finance Minister on February 1st, 2023. The Union Budget for this year was primarily aimed at boosting the Indian economy and revitalising it. The real estate...

Sphot’23 Concludes with Exciting Possibilities for Real-World AI Applications

Sphot'23 concluded with the launch of Pravid, Saarthi's cutting-edge Communication AI platform.

Union Budget 2023-24: What It Means for the Future of the Automotive Sector?

Union Budget 2023-24: A Post-Budget Perspective on the Indian Automotive Sector.

Business Leaders Give Thumbs Up to Union Budget 2023’s Growth-Focused Provisions

Understand the impact of the Union Budget 2023-24 on the Indian economy through the eyes of business leaders and why they are optimistic about its potential.

SBICAPS opens new office in Bengaluru, to focus on infrastructure, defence and start-ups

BENGALURU, India | 1st February 2023: SBI Capital Markets Limited (SBICAPS), a wholly owned subsidiary and investment banking arm of State Bank of India (SBI) on Monday announced the opening of its office in Bengaluru. Inaugurated by Shri Dinesh Khara, Chairman, SBI, in the presence of Shri Swaminathan J, Managing Director (CB...

Vedanta Aluminium Raises USD 250 Mn in Sustainability Linked Loans

New Delhi, Delhi, India | 1st February 2023: Vedanta Aluminium, India’s largest producer of aluminium, has raised USD 250 million through Sustainability Linked Loans (SLL) from leading international banks, for financing its capex initiatives and reducing carbon footprint. The loans were granted on the basis of specific performance parameters...

Dr. Stephen Kahane Joins Suki’s Board of Directors to Elevate Voice AI in Healthcare

Voice AI Technology for Healthcare Gets a Boost with Dr. Kahane on Suki's Board.